e-learning
resources
Milan 2017
Sunday, 10.09.2017
Airway disease and exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Baseline serum CCL5 as a predictor for loss of asthma control and exacerbation during step-wise treatment reduction.
N. Mohd Aminudin (shah alam, Malaysia)
Source:
International Congress 2017 – Airway disease and exacerbations
Session:
Airway disease and exacerbations
Session type:
Thematic Poster
Number:
1129
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Mohd Aminudin (shah alam, Malaysia). Baseline serum CCL5 as a predictor for loss of asthma control and exacerbation during step-wise treatment reduction.. 1129
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Elevated blood eosinophils on admission for a severe exacerbation of COPD is not a predictor for survival
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017
Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function
Source: Annual Congress 2007 - Mechanisms of airway inflammation
Year: 2007
Increased serum endotoxin levels as biomarker in acute exacerbations of COPD.
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Low hematocrit as predictor of exacerbation frequency in COPD patients
Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation
Year: 2010
Patient baseline variables predict future asthma control status and risk of exacerbations
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline
Source: International Congress 2017 – Infection and exacerbation science
Year: 2017
Increased serum IL-17 is an independent risk factor for severe asthma
Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity
Year: 2008
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 141s
Year: 2002
Sputum VEGF level increases with treatment of COPD acute exacerbation
Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation
Year: 2012
Serum levels of IL-6 in adult patients with moderate to severe asthma.
Source: International Congress 2017 – Novel mechanisms in asthma
Year: 2017
Is serum leptin level a predictor for asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 681s
Year: 2005
The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL
Source: Eur Respir J 2005; 26: Suppl. 49, 298s
Year: 2005
Correlations between exacerbation rate and blood eosinophil levels in COPD patients
Source: International Congress 2017 – Infection and exacerbation science
Year: 2017
Increased serum IL-17 does not predict future risk and impairment in asthma
Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Year: 2009
The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants
Source: Eur Respir J 2002; 20: Suppl. 38, 312s
Year: 2002
Longitudinal measurement of airway inflammation relates to a higher risk of exacerbation in COPD.
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
The role of Hs-CRP in evaluating asthma severity and asthma control
Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up
Year: 2010
Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation
Source: Eur Respir J 2005; 26: Suppl. 49, 284s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept